Literature DB >> 35475636

parC Variants in Mycoplasma genitalium: Trends over Time and Association with Moxifloxacin Failure.

Gerald L Murray1,2,3, Kaveesha Bodiyabadu1,2,3, Lenka A Vodstrcil4,5, Dorothy A Machalek1,2,6, Jennifer Danielewski1,2, Erica L Plummer1,2,4,5, Suzanne M Garland1,2,3, David M Whiley7,8, Emma L Sweeney7, Catriona S Bradshaw4,5,9.   

Abstract

Prevalence, trends, and treatment outcome estimates were generated for parC variants in macrolide-resistant Mycoplasma genitalium. Among 539 cases, the most common amino acid change was S83I, which increased from 13% in 2012 to 2013, to 23% in 2019 to 2020 (Ptrend = 0.046). From 381 moxifloxacin treatments, failure occurred in 58.7% (95% confidence interval [CI], 46.7 to 69.9) of cases with S83I. Other changes affecting S83 or D87 were uncommon and minor contributors to failure. The absence of S83I was highly predictive of moxifloxacin cure (96.4%; 95% CI, 93.7 to 98.2), highlighting diagnostic potential.

Entities:  

Keywords:  Mycoplasma genitalium; antibiotic resistance; fluoroquinolone; moxifloxacin; parC

Mesh：

Substances：

Year:  2022        PMID： 35475636      PMCID： PMC9112906          DOI： 10.1128/aac.00278-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  12 in total

1.  Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment.

Authors:  T Deguchi; S Maeda; M Tamaki; T Yoshida; H Ishiko; M Ito; S Yokoi; Y Takahashi; S Ishihara
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

2.  Moxifloxacin and Sitafloxacin Treatment Failure in Mycoplasma genitalium Infection: Association with parC Mutation G248T (S83I) and Concurrent gyrA Mutations.

Authors:  Gerald L Murray; Kaveesha Bodiyabadu; Jennifer Danielewski; Suzanne M Garland; Dorothy A Machalek; Christopher K Fairley; Jørgen S Jensen; Deborah A Williamson; Lit Y Tan; Elisa Mokany; Duygu Durukan; Catriona S Bradshaw
Journal:  J Infect Dis       Date:  2020-03-02       Impact factor: 5.226

3.  Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis.

Authors:  Dorothy A Machalek; Yusha Tao; Hannah Shilling; Jørgen S Jensen; Magnus Unemo; Gerald Murray; Eric P F Chow; Nicola Low; Suzanne M Garland; Lenka A Vodstrcil; Christopher K Fairley; Jane S Hocking; Lei Zhang; Catriona S Bradshaw
Journal:  Lancet Infect Dis       Date:  2020-07-02       Impact factor: 25.071

4.  Analysis of fluoroquinolone-resistance using MIC determination and homology modelling of ParC of contemporary Mycoplasma genitalium strains.

Authors:  Ryoichi Hamasuna; Hiroyuki Hanzawa; Ayako Moritomo; Masahiro Matsumoto; Hisami Aono; Ikko Tomisaki; Takaaki Akasaka; Naohiro Fujimoto; Jørgen Skov Jensen
Journal:  J Infect Chemother       Date:  2021-11-24       Impact factor: 2.211

5.  Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens.

Authors:  Melanie Bissessor; Sepehr N Tabrizi; Jimmy Twin; Houda Abdo; Christopher K Fairley; Marcus Y Chen; Lenka A Vodstrcil; Jorgen S Jensen; Jane S Hocking; Suzanne M Garland; Catriona S Bradshaw
Journal:  Clin Infect Dis       Date:  2014-12-23       Impact factor: 9.079

6.  Resistance-Guided Antimicrobial Therapy Using Doxycycline-Moxifloxacin and Doxycycline-2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability.

Authors:  Duygu Durukan; Tim R H Read; Gerald Murray; Michelle Doyle; Eric P F Chow; Lenka A Vodstrcil; Christopher K Fairley; Ivette Aguirre; Elisa Mokany; Lit Y Tan; Marcus Y Chen; Catriona S Bradshaw
Journal:  Clin Infect Dis       Date:  2020-09-12       Impact factor: 9.079

Review 7.  Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care.

Authors:  Emma L Sweeney; Catriona S Bradshaw; Gerald L Murray; David M Whiley
Journal:  Lancet Infect Dis       Date:  2022-03-21       Impact factor: 71.421

8.  Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium.

Authors:  Gerald L Murray; Catriona S Bradshaw; Melanie Bissessor; Jennifer Danielewski; Suzanne M Garland; Jørgen S Jensen; Christopher K Fairley; Sepehr N Tabrizi
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

9.  Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains.

Authors:  Ryoichi Hamasuna; Phuong Thi Le; Satoshi Kutsuna; Keiichi Furubayashi; Masahiro Matsumoto; Norio Ohmagari; Naohiro Fujimoto; Tetsuro Matsumoto; Jorgen Skov Jensen
Journal:  PLoS One       Date:  2018-06-08       Impact factor: 3.240

10.  Outcomes of Resistance-guided Sequential Treatment of Mycoplasma genitalium Infections: A Prospective Evaluation.

Authors:  Tim R H Read; Christopher K Fairley; Gerald L Murray; Jorgen S Jensen; Jennifer Danielewski; Karen Worthington; Michelle Doyle; Elisa Mokany; Litty Tan; Eric P F Chow; Suzanne M Garland; Catriona S Bradshaw
Journal:  Clin Infect Dis       Date:  2019-02-01       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.